Genedata provides fully integrated enterprise workflow platform to connect data generation, processing, and sharing across R&D sites at Ferring
August 17, 2021
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Ferring Pharmaceuticals has adopted Genedata Bioprocess® to support end-to-end protein and antibody development processes in their newly formed Biologics Technologies and Development R&D units. With a focus on key therapeutic areas of reproductive medicine & maternal health, gastroenterology, and onco-urology, Ferring will use the Genedata platform to accelerate development of novel peptide-based drugs and biotechnology-derived medicines, such as recombinant proteins and other biologicals. Genedata will provide a fully integrated enterprise workflow platform to connect data generation, processing, and sharing across Ferring R&D sites.
“As part of our growth strategy in innovative biopharmaceuticals, we needed a central platform to capture and process data across our global R&D teams, while ensuring full data integrity and traceability, and Genedata was the only solution that ticked all the boxes right from the start,” said Bjoern Hock, Ph.D., VP Biologics Technologies and Development at Ferring Pharmaceuticals. “Without having to embark on a lengthy and costly customization project, Ferring was able to take advantage of Genedata’s off-the-shelf platform and immediately start using the software across all our R&D sites. The Genedata platform also supports our quality and compliance requirements, functionality completely missing in the other solutions we looked at,” continued Hock.
Since 2018, Ferring pharmaceuticals has embarked on strategic investments in biotherapeutic R&D, highlighted by their new state-of-the-art innovation center in Lausanne, Switzerland. The Genedata platform has been chosen as part of Ferring’s digitalization strategy to ensure full traceability throughout their global organization across process development workflows, including cell line development, cell banking, upstream process development (USP), downstream process development (DSP), formulation development (FD), analytical development (AD), laboratory management, and screening assays. These combined investments underscore Ferring’s strategy to strengthen capabilities and expertise in new biologic agents, such as recombinant proteins and monoclonal antibodies, as it continues to grow.
“We are very pleased that Ferring has chosen Genedata as their digitalization partner to support their rapidly expanding biotherapeutic drug development operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “Bioprocess development comes with specific functional as well as regulatory and compliance requirements, and we are committed to further invest into our Biopharma Platform to address future development and CMC requirements that enable our customers to bring better biopharmaceuticals more quickly to the market.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.